A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

Practical management of tyrosine kinase inhibitor-associated side effects in GIST

(2010) Heikki Joensuu et al.   CANCER TREATMENT REVIEWS

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2010) E Jabbour et al.   LEUKEMIA

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials

(2009) Sogol Amjadi et al.   ARTHRITIS AND RHEUMATISM

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model

(2009) Minglun Li et al.   Radiation Oncology

Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study

(2009) D. Khanna et al.   RHEUMATOLOGY

Role of PDGF in fibrotic diseases and systemic sclerosis

(2008) M. Trojanowska   RHEUMATOLOGY

Imatinib as a novel therapeutic approach for fibrotic disorders

(2008) J. H. W. Distler et al.   RHEUMATOLOGY

Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation

(2007) Gerald S. Horan et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE